Race Oncology (ASX:RAC) has announced that the investigator-sponsored Phase 1b/2 trial of bisantrene in combination with clofarabine and fludarabine in relapsed or refractory acute myeloid leukaemia patients has been successfully concluded having achieved its primary endpoint for efficacy. …
Race Oncology says Phase 2 trial of Bisantrene meets predetermined efficacy criteria
July 30, 2024 Latest NewsAustralian Biotech
Latest Video
New Stories
-
The 'Dispatched' Podcast - Week in review
August 7, 2026 - - Podcast -
argenx partners with Monash University and Myostellar to develop muscular therapies
August 7, 2026 - - Latest News -
A new generation is rewriting their lives living with Cystic Fibrosis
August 7, 2026 - - Latest News -
US approves Moderna's mRNA flu vaccine in major technology milestone
August 7, 2026 - - Latest News -
If Australian companies shun their domestic market, who can blame multinationals?
August 6, 2026 - - Latest News -
Neuren reports record DAYBUE sales as royalties rise and global expansion nears
August 6, 2026 - - Australian Biotech -
Moderna begins Phase 1 trial of vaccine candidate against Bundibugyo Ebola Virus
August 6, 2026 - - Latest News